

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## Beijing Biostar Pharmaceuticals Co., Ltd.

### 北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2563)

## POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 26 JUNE 2026

References are made to the supplemental notice of annual general meeting dated 11 June 2026 and notice of annual general meeting dated 28 May 2026 (the “**AGM Notice**”), supplemental circular dated 11 June 2026 and circular dated 28 May 2026 (the “**Circular**”) of Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”). Capitalised terms used in this announcement shall have the same meanings as those defined in the Circular, unless otherwise specified herein.

### POLL RESULTS OF THE ANNUAL GENERAL MEETING

The Board is pleased to announce that at the AGM held on 26 June 2026, all the ordinary resolutions (“**Ordinary Resolutions**”) (save for the ordinary resolution numbered 7 which was withdrawn prior to the AGM) and the special resolutions “**Special Resolutions**” (save for the special resolutions numbered 14 and 15 which were also withdrawn prior to the AGM), together with the Ordinary Resolutions, referred to as, the “**Resolutions**” as set out in the AGM Notice were duly passed by the Shareholders by way of poll. The poll results in respect of the Resolutions passed at the AGM were as follows:

ORDINARY RESOLUTIONS		No. of votes cast and percentage of total number of votes cast	
		For	Against
1.	To consider and approve the audited consolidated financial statements for the year ended 31 December 2025.	204,781,934 (77.097207%)	60,833,309 (22.902793%)
2.	To consider and approve the annual report of the Company for the year ended 31 December 2025.	204,781,934 (77.097207%)	60,833,309 (22.902793%)
3.	To consider and approve the profit distribution proposal of the Company for the year ended 31 December 2025.	264,056,156 (99.413028%)	1,559,087 (0.586972%)

ORDINARY RESOLUTIONS		No. of votes cast and percentage of total number of votes cast	
		For	Against
4.	To consider and approve the report of the board of directors (the “ <b>Board</b> ”) of the Company for the year ended 31 December 2025.	204,781,934 (77.097207%)	60,833,309 (22.902793%)
5.	To consider and approve the duty report of independent non-executive Director for the year ended 31 December 2025.	204,781,934 (77.097207%)	60,833,309 (22.902793%)
6.	To consider and approve the report of the supervisors committee of the Company for the year ended 31 December 2025.	204,781,934 (77.097207%)	60,833,309 (22.902793%)
7.	To consider and ratify the connected transaction for the year ended 31 December 2025.	This resolution was withdrawn prior to the AGM and was not proposed for Shareholders’ consideration and voting at the AGM.	
8.	To consider and approve the Company’s directors’ remuneration package for the year ending 31 December 2026.	190,812,274 (75.825799%)	60,833,309 (24.174201%)
9.	To consider and appoint Dr. Zhu Xiaodong as the independent non-executive Director.	204,781,934 (88.720493%)	26,035,013 (11.279507%)
10.	To consider and approve the re-appointment of WUYIGE Certified Public Accountants LLP as the auditor of the Company for the year ending 31 December 2026, and to authorize the Board to determine their remuneration.	204,781,934 (77.097207%)	60,833,309 (22.902793%)

SPECIAL RESOLUTION		No. of votes cast and percentage of total number of votes cast	
		For	Against
11.	To consider and approve the proposed granting of the general mandate to the Board to issue new Shares.	168,985,013 (67.151989%)	82,660,570 (32.848011%)
12.	To consider and approve the proposed granting of the general mandate to the Board to repurchase H Shares.	168,985,013 (63.620224%)	96,630,230 (36.379776%)
13.	To consider and approve the proposed cancellation of the supervisory committee and amendments to the Articles of Association.	168,985,013 (63.620224%)	96,630,230 (36.379776%)

SPECIAL RESOLUTION		No. of votes cast and percentage of total number of votes cast	
		For	Against
14.	To consider and adopt the Share Option Scheme.	This resolution was withdrawn prior to the AGM and was not proposed for Shareholders' consideration and voting at the AGM.	
15.	To consider and authorised the Board and/or Authorisation Person to handle matters pertaining to the Share Option Scheme.	This resolution was withdrawn prior to the AGM and was not proposed for Shareholders' consideration and voting at the AGM.	

As more than 50% of the votes were cast in favour of each of the Ordinary Resolutions numbered 1 to 6 and numbered 8 to 10 above, the Ordinary Resolutions numbered 1 to 6 and numbered 8 to 10 above were duly passed as Ordinary Resolutions of the Company. As not less than two-third of the votes were cast in favour of the special resolutions numbered 11, the special resolution was duly passed as a special resolution of the Company.

As ordinary resolution numbered 9 was duly passed. Dr. Zhu Xiaodong was duly elected and appointed as the independent non-executive Director of the Company with effect from the conclusion of the AGM.

As less than two-third of the votes were cast in favour of the special resolutions numbered 12 to 13, the special resolutions were not duly passed as special resolutions of the Company.

As disclosed in the supplemental circular dated 11 June 2026, the ordinary resolution numbered 7 regarding the ratification of the connected transaction and the special resolutions numbered 14 and 15 regarding the adoption of the Share Option Scheme (the “**Withdrawn Resolutions**”) were withdrawn prior to the AGM. Accordingly, the Withdrawn Resolutions were not proposed at the AGM for Shareholders' consideration and voting, and no poll was taken or counted in respect thereof.

As at the date of the AGM, the total number of issued Shares was 364,588,000 Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against all the resolutions at the AGM (save for the Withdrawn Resolutions as stated above). There were no Shares entitling the holders to attend and abstain from voting in favour of any of the resolutions at the AGM as set out in Rule 13.40 of the Listing Rules. No other Shareholder was required under the Listing Rules to abstain from voting on any of the resolutions at the AGM. No Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the above resolutions.

All the then Directors of the Company, namely Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng, Dr. Guan Jin, Mr. Tang Jin, Ms. Dai Xuefen, Mr. Shiu Shu Ming and Dr. Ye Chengang, attended the AGM either in person or by electronic means.

The Company's Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer at the AGM for the vote-taking.

By order of the Board  
**Beijing Biostar Pharmaceuticals Co., Ltd.**  
北京華昊中天生物醫藥股份有限公司  
**Dr. Tang Li**  
*Chairperson and Executive Director*

Beijing, the PRC, 26 June 2026

*As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Mr. Shiu Shu Ming, Dr. Ye Chengang and Dr. Zhu Xiaodong as independent non-executive Directors.*